s adjuvant every week (3.0 mg/each peptide

8 trials

Sponsors

Kurume University Cancer Vaccine Center

Conditions

colorectal cancerendocrine malignant tumorsesophageal cancergastric cancerhead and neck cancerhematological malignancylung cancerskin cancer

Phase 2

Phase II randomised clinical trial of personalized peptide vaccination in combination with Dai-kenchu-to for colorectal cancer patients resistant to standard therapies.

Active, not recruitingJPRN-UMIN000008126

Kurume University Cancer Vaccine Centercolorectal cancer

Start: 2012-06-04Target: 60Updated: 2026-06-29

Phase II clinical trial of personalized peptide vaccination for patient with advanced esophageal cancer resistant to standard therapies .

Active, not recruitingJPRN-UMIN000008824

Kurume University Cancer Vaccine Centeresophageal cancer

Start: 2012-09-01Target: 50Updated: 2026-06-29

Phase II clinical trial of personalized peptide vaccination for patient with advanced skin cancer resistant to standard therapies .

Active, not recruitingJPRN-UMIN000008828

Kurume University Cancer Vaccine Centerskin cancer

Start: 2012-09-01Target: 50Updated: 2026-06-29

Phase II clinical trial of personalized peptide vaccination for patient with advanced head and neck cancer resistant to standard therapies .

Active, not recruitingJPRN-UMIN000008825

Kurume University Cancer Vaccine Centerhead and neck cancer

Start: 2012-08-23Target: 50Updated: 2026-06-29

Phase II clinical trial of personalized peptide vaccination for patient with advanced endocrine malignant tumors resistant to standard therapies .

Active, not recruitingJPRN-UMIN000008826

Kurume University Cancer Vaccine Centerendocrine malignant tumors

Start: 2012-09-01Target: 50Updated: 2026-06-29

Phase II clinical trial of personalized peptide vaccination for patient with advanced hematological malignancy resistant to standard therapies .

Active, not recruitingJPRN-UMIN000008823

Kurume University Cancer Vaccine Centerhematological malignancy

Start: 2012-09-01Target: 50Updated: 2026-06-29

Phase II randomised clinical trial of personalized peptide vaccination in combination with Juzen-taiho-to for gastric cancer patients resistant to standard therapies .

Active, not recruitingJPRN-UMIN000008827

Kurume University Cancer Vaccine Centergastric cancer

Start: 2012-09-01Target: 60Updated: 2026-06-29

Phase II randomised clinical trial of personalized peptide vaccination in combination with Ninjin-yoei-to for lung cancer patients resistant to standard therapies .

Active, not recruitingJPRN-UMIN000008940

Kurume University Cancer Vaccine Centerlung cancer

Start: 2012-09-19Target: 80Updated: 2026-06-29